Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics. Its lead product candidate, ELVN-001, is a potent, highly selective ATP-competitive tyrosine kinase inhibitor targeting BCR-ABL, the oncogenic driver of chronic myeloid leukemia (CML). ELVN-001 is being evaluated in the Phase 1 ENABLE clinical trial, with a Phase 3 pivotal trial (ENABLE-2) planned for initiation in the second half of 2026.
Q2 FY2026 — expected 2026-08-11
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-03 | 2025-12-31 | 0001193125-26-088232 | EDGAR | 100K words |
| 2025-03-13 | 2024-12-31 | 0000950170-25-038758 | EDGAR | 101K words |
| 2024-03-14 | 2023-12-31 | 0000950170-24-031495 | EDGAR | 98K words |
| 2023-02-10 | 2022-12-31 | 0001564590-23-001729 | EDGAR | 70K words |
| 2022-03-15 | 2021-12-31 | 0001564590-22-010216 | EDGAR | — |
| 2021-03-05 | 2020-12-31 | 0001564590-21-011098 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-05 | 2026-06-30 | 0001193125-26-335155 | EDGAR | 78K words |
| 2025-11-12 | 2025-09-30 | 0001193125-25-277619 | EDGAR | 78K words |
| 2025-08-13 | 2025-06-30 | 0001193125-25-179845 | EDGAR | 76K words |
| 2025-05-14 | 2025-03-31 | 0000950170-25-071412 | EDGAR | 74K words |
| 2024-11-13 | 2024-09-30 | 0000950170-24-126332 | EDGAR | 76K words |
| 2024-08-13 | 2024-06-30 | 0000950170-24-096239 | EDGAR | 74K words |
| 2024-05-14 | 2024-03-31 | 0000950170-24-059573 | EDGAR | 72K words |
| 2023-11-09 | 2023-09-30 | 0000950170-23-062080 | EDGAR | 76K words |
| 2023-08-10 | 2023-06-30 | 0000950170-23-041349 | EDGAR | 75K words |
| 2023-05-11 | 2023-03-31 | 0000950170-23-021262 | EDGAR | 73K words |
| 2022-10-25 | 2022-09-30 | 0001564590-22-035098 | EDGAR | — |
| 2022-08-03 | 2022-06-30 | 0001564590-22-027795 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-08-05 | 0001193125-26-335101 | EDGAR | 2K words |
| 2026-03-03 | 0001193125-26-088195 | EDGAR | 2K words |
| 2026-01-07 | 0001193125-26-005535 | EDGAR | 1K words |
| 2025-12-11 | 0001193125-25-315196 | EDGAR | 1K words |
| 2025-11-12 | 0001193125-25-277580 | EDGAR | 2K words |
| 2025-08-13 | 0001193125-25-179837 | EDGAR | 2K words |
| 2025-06-25 | 0001193125-25-146874 | EDGAR | 1K words |
| 2025-06-16 | 0001193125-25-141085 | EDGAR | 1K words |
| 2025-06-13 | 0001193125-25-140285 | EDGAR | 2K words |
| 2025-05-14 | 0000950170-25-071387 | EDGAR | 2K words |
97 total filings indexed. 69 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001672619 |
| Ticker | ELVN |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.enliventherapeutics.com |
| Listed | 2023-02-24 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/ELVN (~200 tokens, structured JSON with cryptographic provenance)